These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27168205)

  • 1. Discussion: Managing Risk When Using Idelalisib.
    Coutre SE; Burger JA; Pagel JM
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):13. PubMed ID: 27168205
    [No Abstract]   [Full Text] [Related]  

  • 2. Abdominal Pain and Bloody Diarrhea.
    Gupta A; Peng L; Li HC
    JAMA Oncol; 2016 Oct; 2(10):1361-1362. PubMed ID: 27442133
    [No Abstract]   [Full Text] [Related]  

  • 3. [Polymicrobial lung infection associated with idelalisib administration].
    Rodríguez-Ferreras A; Velasco-Roces L; Lázaro-López E; Zapico-García I
    Farm Hosp; 2018 Jan; 42(1):25-26. PubMed ID: 29306311
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia.
    Lafon-Desmurs B; Monsel G; Leblond V; Papo M; Caumes E; Fekkar A; Jaureguiberry S
    Med Mal Infect; 2017 Jun; 47(4):293-296. PubMed ID: 27818019
    [No Abstract]   [Full Text] [Related]  

  • 5. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity.
    Castillo JJ; Gustine JN; Meid K; Dubeau T; Yang G; Xu L; Hunter ZR; Treon SP
    Leuk Lymphoma; 2017 Apr; 58(4):1002-1004. PubMed ID: 27562445
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of adverse events associated with idelalisib treatment: expert panel opinion.
    Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
    Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 8. Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
    Hammami MB; Al-Taee A; Meeks M; Fesler M; Hurley MY; Cao D; Lai JP
    Clin J Gastroenterol; 2017 Apr; 10(2):142-146. PubMed ID: 28025783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
    Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
    Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib: deaths from infections. Toxicity and doubtful efficacy.
    Prescrire Int; 2016 Oct; 25(175):243. PubMed ID: 30688423
    [No Abstract]   [Full Text] [Related]  

  • 11. Idelalisib induced CMV gastrointestinal disease: the need for vigilance with novel therapies.
    Goldring L; Kumar B; Gan TE; Low MSY
    Pathology; 2017 Aug; 49(5):555-557. PubMed ID: 28693750
    [No Abstract]   [Full Text] [Related]  

  • 12. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
    Hanlon A; Brander DM
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Grave diarrhea associated with idelalisib administration].
    Suárez Del Olmo D; Corregidor Luna L; Hidalgo Correas FJ; García Benayas E; García Díaz B
    Farm Hosp; 2016 May; 40(3):227-9. PubMed ID: 27145392
    [No Abstract]   [Full Text] [Related]  

  • 14. Multiple mucosal ulcerations caused by idelalisib.
    Galeone M; Antiga E
    Int J Dermatol; 2017 Sep; 56(9):e180-e181. PubMed ID: 28244069
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.
    Machan S; Plaza C; Pérez-González Y; Rodriguez-Pinilla M; Requena L; Cordoba R
    J Med Case Rep; 2020 Feb; 14(1):35. PubMed ID: 32093776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib-induced pneumonitis.
    Gupta A; Li HC
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27485880
    [No Abstract]   [Full Text] [Related]  

  • 17. Colitis due to idelalisib in a patient with follicular lymphoma.
    Canelo-Vilaseca M; Ribera Santasusana JM; Sancho Cia JM
    Med Clin (Barc); 2022 Jul; 159(2):106. PubMed ID: 35525678
    [No Abstract]   [Full Text] [Related]  

  • 18. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
    Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
    Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.
    Barbieux S; Boyle EM; Baillet C; Demarquette H; Vermersch P; Morschhauser F; Herbaux C
    Curr Res Transl Med; 2018 Sep; 66(3):87-89. PubMed ID: 30191811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis.
    Yeung CC; Hockenbery DM; Westerhoff M; Coutre SE; Sedlak RH; Dubowy RL; Munugalavadla V; Taylor K; Bosch F
    Future Oncol; 2018 Sep; 14(22):2265-2277. PubMed ID: 29569483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.